DR. DOPING

Instructions

Logo DR. DOPING

Instructions / Instruction for use: Premarin

I want this, give me price

Active substance: Estrogens conjugatate

ņ“’ Code: G03CA57 Estrogens conjugatate

Pharmacological groups

Estrogens, gestagens; their homologues and antagonists

Antineoplastic hormonal agents and hormone antagonists

Nosological classification (ICD-10)

C61 Malignant neoplasm of prostate

Adenocarcinoma of the prostate, Hormone-dependent prostate cancer, Hormone-Resistant Prostate Cancer, Malignant tumor of prostate, Malignant neoplasm of prostate, Carcinoma of the prostate, Locally-distributed non-metastatic prostate cancer, Locally advanced prostate cancer, Locally spread prostate cancer, Metastatic prostatic carcinoma, Metastatic prostate cancer, Metastatic hormone-resistant prostate cancer, Non-metastatic prostate cancer, Incompatible prostate cancer, Prostate Cancer, Prostate cancer, Common prostate cancer, Testosterone-Depot Prostate Cancer

E28 Ovarian dysfunction

Dysfunction of the sex glands, Abnormal ovarian function, Non-functioning ovaries, Primary dysfunction of the ovaries, Decreased function of the sex glands, Estrogen insufficiency

M81.0 Postmenopausal osteoporosis

Menopause osteoporosis, Osteoporosis in menopause, Osteoporosis in menopause, Osteoporosis in postmenopausal women, Osteoporosis in the postmenopausal period, Postmenopausal osteoporosis, Osteoporosis in postmenopausal women, Perimenopausal osteoporosis, Postmenopausal osteoporosis, Post-menopausal osteoporosis, Postmenopausal osteoporosis, Postmenopausal demineralization of bones, Osteoporosis with estrogen deficiency, Osteoporosis in postmenopausal women, Osteoporosis in postmenopausal women and after hysterectomy

N91 Lack of menstruation, meager and rare menstruation

Amenorrhea, Amenorrhea hypogonadotropic, Amenorrhea is prolactin-dependent, Oligomenorrhoea, Shortening of the secretory phase of the menstrual cycle, Menstrual disorders, Menstruation disorders, Prolactin-dependent amenorrhea without galactorrhea

N93 Other abnormal bleeding from the uterus and vagina

Atonic uterine bleeding, Prolonged menstruation, Blood loss during menstruation, Bleeding from the genitourinary system, Bleeding uterine dysfunctional, Bleeding from the genital tract of organic etiology, Uterine bleeding, Menorrhagia with fibroids, Functional uterine bleeding, Abnormal bleeding from the genitals in women

N94.6 Dysmenorrhea Unspecified

Pain during menstruation, Functional disorders of the menstrual cycle, Menstrual cramps, Emmeniopathy, Pain during menstruation, Painful menstrual irregularities, algomenorrhea, algomenoreya, Pain smooth muscle spasm, Pain spasm of smooth muscles (renal and biliary colic, intestinal spasms, dysmenorrhea), Pain spasm of smooth muscles of internal organs (kidney and biliary colic, intestinal spasms, dysmenorrhea), Disalgomenoreya, dysmenorrhea, Dysmenorrhea (essential) (Exfoliative), menstrual disorder, menstruation painful, metrorrhagia, Violation of the menstrual cycle, Menstrual irregularities, Prolaktinzavisimoe menstrual disorders, Prolaktinzavisimoe menstrual dysfunction, Pain spasm of smooth muscles of internal organs, Spasmodic dysmenorrhea, Primary disalgomenoreya

N95.1 menopausal and menopausal status of women

Atrophy of the mucosa of the lower genital tract, caused by estrogen deficiency; Vaginal dryness; Autonomic dysfunction in women; gipoestrogeniya state; Deficiency of estrogen in menopausal women; Degenerative changes of the mucous membrane in the menopause; Natural menopause; an intact uterus; climacteric; Menopause women; Menopause in women; menopausal depression; Climacteric ovarian dysfunction; Menopause; Climacteric neurosis; Menopause; Menopausal symptoms complicated psychovegetative; Climacteric syndrome; Climacteric vegetative disorders; Climacteric psychosomatic disorder; menopausal disorders; Menopausal disorders in women; menopausal condition; Climacteric vascular disorders; Menopause; Menopausal vasomotor symptoms; menopausal period; Lack of estrogen; Feeling the heat; Pathological menopause; perimenopause; menopause; postmenopausal; Premature menopause; premenopauznom period; tides; hot flashes; flushing in the Meno and postmenopausal; Hot flashes / hot flashes in menopause; Heart attack during menopause; Early menopause in women; Disorders of menopause; climacteric syndrome; Vascular complications of menopause; Physiological menopause; Estrogendefitsitnye state; premature Menopause

Composition and form of release

1 tablet contains conjugated estrogens 0.625 mg; in the box 1 blister for 28 pcs.

pharmachologic effect

The pharmacological action is estrogenic.

It binds to estrogen receptors of target cells.

Pharmacodynamics

It alleviates or eliminates manifestations of climacteric syndrome (fever, sweating, dizziness, irritability, depressive state), prevents the development of osteoporosis, prevents the involution of the genital organs, normalizes the menstrual cycle in women of childbearing age, lowers testosterone levels in men.

Indications

Climacteric syndrome, estrogen deficiency in the menopausal and postmenopausal period, postmenopausal osteoporosis, dysfunctional uterine bleeding, dysmenorrhea, amenorrhea, prostate cancer.

Contraindications

Breast cancer and estrogen-dependent neoplasms; uterine bleeding of unclear etiology; thrombophlebitis, a disorder of the blood coagulation system, thromboembolic diseases; severe diseases of the cardiovascular system; marked violations of the liver or kidneys; sickle-cell anemia; congenital hearing loss; prolonged immobilization.

pregnancy and lactation

Contraindicated in pregnancy.

Side effects

Headache, nausea, vomiting, weight gain, swelling, uterine bleeding, facial skin pigmentation, erythema nodosum, transient elevation of transaminase levels in blood plasma, hyperbilirubinemia; allergic reactions (rash); rarely - hemorrhagic rashes on the skin, neoplasms of the endometrium.

Interaction

The effect is reduced by barbiturates, hydantoins, butadione, rifampicin.

Dosing and Administration

Inside. For cyclic use - 625 mcg - 1.25 mg per day, alternating with the reception for 3 weeks with a break in 1 week, menstrual bleeding begins with the 5th day of the menstrual cycle, and from the 15th to the 21st day in addition use a gestagenic the drug (with prolonged absence of menstruation, treatment is started any day). If necessary, on the 5th-7th day of treatment, the daily dose can be increased to 3.75 mg, then it is reduced to 1.25 mg. Treatment of malignant neoplasms is 3.75-7.5 mg.

Precautionary measures

Caution is prescribed for diabetes mellitus, arterial hypertension, epilepsy, multiple sclerosis, porphyria, tetany, mastopathy, thyrotoxicosis.

Storage Conditions

In the dark place at a temperature of 15-25 į C.

Keep out of the reach of children.

Shelf life

5 years.

Do not use after the expiry date printed on the package.

Someone from the United Arab Emirates - just purchased the goods:
AndroDoz 410 mg 60 capsules